In Brief: Rhone-Poulenc Rorer Lovenox
Rhone-Poulenc Rorer Lovenox: FDA's Cardiovascular & Renal Drugs Advisory Committee will review Lovenox (enoxaparin) injection (NDA 20-614) with aspirin for the treatment of unstable angina and non-Q-wave myocardial infarction at its June 26 meeting. Neurex' Corlopam (NDA 19-922) will also be reviewed at the meeting ("The Pink Sheet" April 21, In Brief). The meeting will be held at the National Institute of Health's Masur Auditorium in Bethesda, Md., starting at 9 a.m...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth